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Summary
Background: With	the	global	efforts	to	eradicate	hepatitis	C	virus	(HCV),	treatment	
during	pregnancy	is	becoming	a	priority	for	research	as	this,	and	maternal	cure	should	
reduce	vertical	transmission.	However,	as	information	on	the	efficacy	and	safety	of	
direct‐acting	antivirals	 (DAAs)	 in	pregnancy	 is	generally	 lacking,	treatment	of	HCV	
infection	during	pregnancy	is	not	currently	recommended.
Aim: To	provide	an	overview	of	current	knowledge	regarding	maternal	exposure,	pla‐
cental	handling	and	safety	of	DAAs	during	pregnancy	and	lactation
Methods: A	literature	search	was	performed	focusing	on	the	effect	of	pregnancy	on	
maternal	exposure	to	DAAs,	the	placental	handling	of	DAAs,	the	safety	of	DAAs	for	
mother	and	child	during	pregnancy	and	the	safety	of	DAAs	during	lactation.
Results: Exposure	to	all	DAAs	studied	is	likely	to	be	altered	during	pregnancy,	mostly	
related	to	pregnancy‐induced	effects	on	drug	absorption	and	metabolism.	Although	
animal	studies	show	that	most	DAAs	are	reported	to	cross	the	placenta	and	transfer	
into	breast	milk,	most	DAA	combinations	show	a	favourable	safety	profile.	Because	
of	the	rapid	viral	decline	after	treatment	initiation,	and	to	avoid	the	critical	period	of	
organogenesis,	treatment	may	be	started	at	the	end	of	the	second	trimester	or	early	
third	trimester.
Conclusions: Treatment	of	HCV	infection	during	pregnancy	is	realistic,	as	DAAs	are	
highly	effective	and	treatment	duration	is	relatively	short.	There	is	an	urgent	need	
to	 study	DAAs	 during	 pregnancy	 and	 lactation	 to	 contribute	 to	 the	 goal	 of	 HCV	
elimination.
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1  | INTRODUC TION
In	2015,	 there	were	 an	estimated	71	million	persons	 chronically	
infected	 with	 hepatitis	 C	 virus	 (HCV),	 resulting	 in	 1.34	 million	
deaths	 that	 year.1	 With	 the	 global	 efforts	 of	 the	World	 Health	
Organization	 to	eradicate	HCV	by	2030,	 it	 is	 important	 to	 iden‐
tify	 individuals	at	risk	and	provide	treatment	as	soon	as	possible	
after	diagnosis.2	While	the	majority	of	infections	among	adults	in	
many	settings	are	 linked	 to	 injection	drug	use,	 the	most	 import‐
ant	source	of	paediatric	HCV	infection	is	vertical	transmission	of	
the	 virus,	 responsible	 for	 approximately	 60%	 of	 paediatric	HCV	
cases	globally.3,4	Among	pregnant	women,	estimates	of	HCV	prev‐
alence	have	ranged	from	0.1%	to	8%	from	different	countries	and	
settings.5‐8
1.1 | Vertical transmission of HCV
A	 large	meta‐analysis	performed	by	Benova	et	al	 reported	a	5.8%	
risk	of	vertical	transmission	of	HCV,	resulting	in	1700	HCV‐infected	
newborns	 in	 the	USA	yearly.9,10	 In	 addition	 to	high	maternal	HCV	
viral	 load,	 the	 review	 states	 that	 maternal	 HIV	 co‐infection	 in‐
creased	the	risk	of	vertical	transmission	of	HCV	to	around	10%.9,11,12 
However,	the	majority	of	the	co‐infected	pregnant	women	included	
were	not	taking	antiretroviral	therapy,	and	a	recent	study	suggested	
that	those	on	antiretroviral	therapy	have	a	similar	risk	of	transmitting	
HCV	to	those	with	HCV	mono‐infection.13	The	prevalence	of	HCV	
and	HIV	co‐infection	among	pregnant	women	varies	across	settings.	
One	study	in	Rwanda	reported	that	3.9%	of	pregnant	women	with	
HCV	were	co‐infected	with	HIV.14	 In	a	Western/Central	European	
cohort	of	pregnant	women	 living	with	HIV,	12%	were	 co‐infected	
with	HCV.14,15	In	addition	to	high	maternal	HCV	viral	load	and	hav‐
ing	HIV,	membrane	rupture	for	more	than	6	hours	before	delivery	
and	 internal	 foetal	 monitoring	 (uterine	 or	 foetal	 scalp)	 have	 been	
reported	to	contribute	to	an	increased	risk	of	vertical	HCV	transmis‐
sion.16	Currently,	most	studies	suggest	that	the	risk	of	transmission	
may	 be	 reduced	 by	 elective	 caesarean	 section,	 particularly	 in	 the	
case	of	HCV/HIV	co‐infection.17‐19	Based	on	timing	of	positive	HCV	
RNA	test	results	in	the	newborn,	timing	of	transmission	is	thought	
to	occur	during	intrauterine,	peripartum	and	postpartum	periods.20 
Transmission	may	 be	most	 frequent	 during	 the	 peripartum	period	
(estimated	40%‐50%)	when	there	is	blood‐blood	contact	during	de‐
livery.	 In	 this	 case,	 the	 child	will	 be	 born	HCV‐RNA	negative,	 but	
detectable	RNA	levels	are	expected	after	the	first	3	days	of	life.	It	is	
estimated	that	intrauterine	transmission	accounts	for	approximately	
30%	of	the	cases,	based	on	HCV‐RNA	positivity	at	or	shortly	after	
delivery.21	The	exact	mechanisms	by	which	intrauterine	transmission	
occurs	are	not	well	understood,	but	may	include	trophoblast‐medi‐
ated	 endocytosis	 of	 HCV	 and/or	 transcytosis	 of	 viral	 particles.22 
Postpartum	transmission	via	breastfeeding	is	rare,	as	the	proportion	
of	children	acquiring	HCV	is	similar	among	those	who	were	breast‐
fed	compared	to	those	who	were	not.17
1.2 | Testing and consequences of HCV 
in the newborn
Although	 vertical	 transmission	 seems	 to	 be	 the	 most	 important	
source	 of	 paediatric	HCV	 infection,	 a	 retrospective	 cohort	 study	
showed	 that	many	 children	 of	women	with	 chronic	HCV	 are	 not	
screened	and	therefore	many	paediatric	HCV	cases	will	be	missed.23 
A	critical	reason	for	the	low	proportion	of	exposed	infants	who	are	
screened	is	related	to	the	delay	in	diagnosis,	as	HCV	antibody	testing	
can	only	be	performed	at	or	after	18	months	of	age,	and	the	chance	
of	loss	to	follow‐up	in	the	intervening	period	is	high.24	Testing	for	
HCV‐RNA	positivity	in	the	newborn	is	generally	not	routinely	per‐
formed,	but	should	be	recommended	in	infants	born	to	HCV‐RNA	
positive	mothers.25	The	majority	 (80%)	of	children	acquiring	HCV	
through	vertical	transmission	do	not	clear	the	infection	spontane‐
ously,	 resulting	 in	 chronic	 paediatric	 HCV	 infection.26	 Although	
liver	injury	from	chronic	HCV	infection	generally	progresses	slowly	
early	 in	 life,	 serious	 liver	damage	can	occur	during	childhood	and	
beyond.27‐29	One	centre	reported	five	children	(out	of	91	included	
patients,	mean	age:	9	years)	with	an	accelerated	course	of	HCV	and	
early	development	of	decompensated	 liver	disease	 requiring	 liver	
transplantation,	 two	of	whom	subsequently	died.30 In addition to 
concerns	 about	 the	 physical	 health	 of	 the	 child	 with	 HCV,	 there	
may	be	high	 levels	of	distress	 in	the	family.31	Treatment	regimens	
based	on	direct‐acting	 antivirals	 (DAAs)	 for	 children	with	 chronic	
HCV	≥	12	years	of	age	or	≥	35	kilograms	were	approved	by	the	FDA	
in	April	2017.32	Phase	I	and	II	trials	of	several	DAA	combinations	for	
children	aged	3‐12	years	are	currently	ongoing	 [ClinicalTrials.gov:	
NCT03067129,	 NCT03080415,	 NCT03487848,	 NCT03022981].	
Unfortunately,	 there	 will	 be	 no	 treatment	 available	 prior	 to	 the	
age	of	3	in	the	near	future	as	this	is	not	requested	by	the	European	
Medicines	 Agency	 (EMA).	 Therefore,	 treatment	 of	 children	 with	
vertically	 acquired	HCV	may	 be	 complicated	 as	 loss	 to	 follow‐up	
in	healthcare	later	in	life	is	likely	to	be	high,	as	is	the	case	in	some	
settings	for	HIV.33,34
1.3 | Effect of HCV on pregnancy outcome
In	addition	to	the	risk	of	vertical	HCV	transmission,	maternal	HCV	
infection	may	 increase	 the	 risk	 of	 adverse	 pregnancy	 outcomes.	
Recently,	a	protocol	has	been	published	for	a	study	which	will	un‐
dertake	 an	 extensive	 systematic	 review	 of	 pregnancy	 outcomes	
in	 women	 with	 HCV;	 results	 are	 expected	 soon.35	 Only	 a	 small	
proportion	of	available	studies	have	sufficient	power	to	adjust	for	
potential	confounding	variables	such	as	tobacco,	alcohol	and	drug	
use.	These	 studies	 report	 an	association	between	maternal	HCV	
infection	and	the	risk	of	gestational	diabetes	and	intrahepatic	chol‐
estasis	of	pregnancy.36,37	In	addition,	an	increased	risk	of	preterm	
birth	was	 reported	and	children	born	 to	women	 living	with	HCV	
were	more	likely	to	have	a	lower	birth	weight	and	to	be	small	for	
gestational	age.38‐41
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1.4 | Considerations for HCV treatment 
during pregnancy
Diagnosis	and	treatment	of	HCV	in	pregnant	women	is	becoming	a	
priority	area	of	research	as	this	has	potential,	not	only	to	cure	the	
mother,	but	also	to	prevent	vertical	transmission.42,43	Until	recently,	
ribavirin	was	a	cornerstone	of	HCV	therapy.	As	this	drug	is	known	
to	be	teratogenic	and	embryotoxic	in	all	animal	species	studied,	its	
use—and	 consequently	 all	 classical	 forms	 of	HCV	 therapy—during	
pregnancy	has	been	contra‐indicated.44	However,	new,	potentially	
much	safer	combinations	of	DAAs	drugs	are	now	available	that	are	
ribavirin	free.	The	relative	short	duration	of	treatment	(8‐12	weeks)	
and	the	rapid	viral	load	decline	following	treatment	initiation	makes	
treatment	and	cure	of	women	with	chronic	HCV	late	in	pregnancy	re‐
alistic.24,45	Testing	and	treatment	during	pregnancy	seems	a	unique	
opportunity,	as	loss	to	follow‐up	of	mother	and	child	postpartum	is	
high	in	many	low	and	middle	income	country	settings,	and	pregnant	
women	are	engaged	 in	healthcare	during	 this	period,	 being	highly	
motivated	to	take	actions	to	ensure	their	own	health	and	the	health	
of	their	unborn	child.23,46,47	 In	2018,	the	American	Association	for	
the	Study	of	Liver	Disease	(AASLD)/Infectious	Diseases	Society	of	
America	 (IDSA)	guidelines	 recommended	universal	HCV	screening	
in	pregnancy	which	was	already	suggested	by	other	countries	such	
as	France	and	Pakistan	a	few	years	earlier.24,48,49	It	is,	however,	not	
being	implemented	widely	thus	far	as	other	guidelines,	such	as	from	
the	Centers	for	Disease	Control	and	Prevention	and	the	Society	for	
Maternal‐Foetal	 Medicine,	 have	 not	 yet	 adopted	 the	 recommen‐
dation.	 It	 is	 estimated	 that	 such	 a	 screening	 strategy,	 followed	by	
treatment	 after	 pregnancy,	 would	 be	 cost‐effective	 for	 maternal	
treatment	 and	would	 identify	 around	 300	 newborns	with	 vertical	
HCV	in	the	USA	annually.50	However,	pregnant	women	may	experi‐
ence	psychological	stress	as	treatment	start	has	to	be	postponed	to	
the	postpartum	period.	A	recent	survey	showed	that	among	women	
with	(a	history	of)	HCV,	60%	were	willing	to	undergo	HCV	therapy	
during	pregnancy	given	the	fact	that	it	would	reduce	the	risk	of	verti‐
cal	transmission,	and	despite	the	lack	of	safety	data.51
Despite	recent	interest	and	major	advancements	in	available	treat‐
ment	options,	data	on	DAAs	in	this	population	are	limited	to	three	ab‐
stracts	on	either	intentional	or	accidental	exposure	during	pregnancy	
in	a	 small	number	of	women.52‐54	There	are	a	number	of	 important	
aspects	 to	consider	prior	 to	 implementation	of	DAA	therapy	during	
pregnancy,	which	we	review	here.	These	are:	(a)	The	effect	of	preg‐
nancy	on	maternal	exposure	 to	DAAs;	 (b)	The	placental	handling	of	
DAAs;	(c)	Safety	of	DAAs	for	mother	and	child	during	pregnancy;	(d)	
Safety	of	DAAs	during	the	lactation	period.	Implementation	and	costs	
of	antenatal	HCV	screening	are	also	important	but	will	not	be	consid‐
ered	here.	We	identify	research	gaps	on	the	potential	use	of	DAAs	in	
pregnant	and	breastfeeding	women	living	with	HCV.
2  | EFFEC T OF PREGNANCY ON 
MATERNAL E XPOSURE TO DIREC T-AC TING 
ANTIVIR AL S
Pregnancy‐associated	 anatomical	 and	 physiological	 changes	 may	
influence	drug	pharmacokinetics	(PK),	in	some	cases	leading	to	the	
need	for	dose	adjustments.55	To	date,	only	one	abstract	is	available	
on	sofosbuvir/daclatasvir	in	pregnancy	and	two	abstracts	on	sofos‐
buvir/ledipasvir.52‐54	 Although	 all	 women	 included	 in	 these	 three	
studies	had	a	rapid	HCV	RNA	response	to	therapy,	no	results	from	
PK	analysis	are	reported	(yet).	Because	of	absence	of	available	clini‐
cal	PK	data	to	date,	the	effect	of	pregnancy‐induced	alterations	on	
drug	disposition	may	be	predicted	based	on	their	PK	properties.	For	
each	DAA,	we	discuss	 the	 impact	of	 pregnancy	on	maternal	DAA	
exposure	by	considering	the	potential	effect	on	drug	absorption,	dis‐
tribution,	metabolism	and	excretion,	as	well	as	potential	drug‐drug	
interactions	 (DDIs)	with	 combination	 antiretroviral	 therapy	 (cART)	
for	treatment	of	HIV.	The	literature	search	strategy	can	be	found	in	
Appendix	S1.	The	expected	pregnancy‐induced	changes	in	maternal	
DAA	exposure	are	described	below	and	summarised	in	Table	1.
2.1 | Absorption
Pregnancy‐induced	alterations	of	gastrointestinal	function,	such	as	
delayed‐gastric	 emptying,	 prolonged	 gastrointestinal	 transit	 time	
and	 reduced	 gastric	 acidity,	 can	 either	 increase	 or	 decrease	 drug	
absorption.55,56	Ledipasvir	and	velpatasvir	show	pH‐dependent	ab‐
sorption,	with	a	decreased	solubility	at	a	higher	pH.	Reduced	gastric	
TA B L E  1  Overview	safety	and	pharmacokinetic	data	of	DAAs	in	pregnancy
DAA combination Genotype
Hypothetical change in maternal exposure 
(mechanism)
Safety concerns based 
on animal data
Priority to be studied in 
clinical trials in pregnancy
SOF/DAC Genotype	1‐4 ↓	DAC	exposure	(CYP3A4	induction) Yes High
SOF/LDV Genotype	1,	4‐6 ↓	LDV	exposure	(gastric	pH	increase) No Moderate
SOF/VEL
SOF/VEL/VOX
Pan‐genotypic ↓	VEL	exposure	(gastric	pH	increase)
↓	VEL/VOX	exposure
(CYP3A4	induction)
Uncertain High
GZR/ELB Genotype	1,4 ↓	GZR/	ELB	exposure	(CYP3A4	induction) No Moderate
GLE/PIB Pan‐genotypic ↓	GLE	exposure	(CYP3A4	induction) Uncertain High
Abbreviations:	DAC,	daclatasvir;	ELB,	elbasvir;	GLE,	glecaprevir;	GZR,	grazoprevir;	LDV,	ledipasvir;	PIB,	pibrentasvir;	SOF,	sofosbuvir;	VEL,	vel‐
patasvir;	VOX,	voxilaprevir.
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acidity	during	pregnancy	may	therefore	result	in	lower	exposure.57,58 
During	pregnancy,	women	often	suffer	from	nausea	and	heartburn	
for	which	antacids	and/or	proton	pump	inhibitors	(PPIs)	may	be	pre‐
scribed.59	 It	has	been	 shown	 that	velpatasvir	 and	 ledipasvir	 expo‐
sure	in	healthy	volunteers	treated	with	PPIs	such	as	omeprazole,	is	
reduced	up	 to	40%.60,61	Therefore,	 co‐administration	of	PPIs	with	
velpatasvir	 or	 ledipasvir	 during	 pregnancy	 should	 be	 avoided	 if	
possible.57,58
2.2 | Distribution
Apart	 from	physiological	changes	 (eg	body	volume	and	tissue	per‐
fusion),	physicochemical	factors	(eg	drug	lipophilicity	and	molecular	
weight)	 determine	 drug	 distribution.	 For	 example,	 the	 increase	 in	
body	fat	during	pregnancy	is	likely	to	increase	the	volume	of	distri‐
bution	of	highly	 lipophilic	drugs,	such	as	DAAs,	which	 in	turn	may	
result	 in	 lower	 peak	 plasma	 levels,	 prolonged	 half‐life	 and	 lower	
amplitude	 of	 plasma	 concentrations	 at	 steady	 state.	 However,	 lit‐
tle	 information	 is	 available	 to	 estimate	 the	 contribution	of	 the	 in‐
creased	 fat	mass	 to	 the	decrease	 in	 plasma	 levels	 often	observed	
during	pregnancy.55,62	All	DAAs,	except	sofosbuvir,	show	a	high	de‐
gree	of	plasma	protein	binding.63	Particularly	for	these	highly	protein	
bound	drugs,	an	increase	in	the	unbound	fraction	may	be	expected	
due	to	decreased	plasma	levels	of	the	main	drug‐binding	plasma	pro‐
teins	albumin	and	α1‐acid	glycoprotein	during	pregnancy.	For	most	
drugs,	the	total	concentration	decreases	during	pregnancy	while	the	
unbound	 concentrations	 are	 unaffected.	 Therefore,	 it	 is	 crucial	 to	
measure	 the	unbound	plasma	concentration	 in	pregnancy,	next	 to	
total	plasma	concentrations,	to	reliably	identify	the	effect	of	preg‐
nancy	on	the	pharmacologically	active	unbound	concentration.	This	
should	be	taken	into	account	in	future	studies	on	DAA	pharmacoki‐
netics	in	pregnancy.64
2.3 | Metabolism
Pregnancy‐induced	changes	in	the	activity	of	drug‐metabolising	en‐
zymes	including	cytochrome	P450	(CYP)	and	the	uridine	diphosphate	
glucuronosyltransferase	 (UGT)	 family	 have	 been	 observed.	While	
the	mechanism	 of	 the	 observed	 changes	 has	 not	 been	 identified,	
accumulated	data	suggest	that	the	changes	are	regulated	by	rising	
concentrations	of	hormones.55	 Increased	CYP3A4	capacity	 in	 liver	
and/or	 intestine	 is	expected	to	have	the	most	profound	impact	on	
DAA	pharmacokinetics	compared	to	other	metabolising	enzymes.65 
Tracy	et	al	reported	that	CYP3A	activity	increased	by	35%‐38%	dur‐
ing	pregnancy66	and,	except	 for	 sofosbuvir/ledipasvir,	 exposure	 to	
all	DAA	combinations	may	be	affected	to	some	extent	by	induction	
of	CYP3A‐mediated	metabolism.	The	use	of	potent	CYP3A	inducers	
in	combination	with	DAAs	that	are	metabolised	by	CYP3A4	is	cur‐
rently	contra‐indicated,	as	 this	may	 reduce	DAA	efficacy,	possibly	
resulting	 in	 virological	 failure.65	 The	moderate	 pregnancy‐induced	
increase	 in	CYP3A4	activity	may	have	 less	profound	effects	 com‐
pared	to	the	effects	of	concomitant	use	of	strong	CYP3A	inducers	
on	DAA	exposure,	but	dose	adjustments	of	DAAs	during	pregnancy	
may	have	to	be	considered.	For	some	DAA	combinations,	only	expo‐
sure	to	a	single	component	may	be	affected	by	pregnancy‐induced	
changes.	 For	 example,	 exposure	 to	 velpatasvir	 and	 voxilaprevir,	
but	not	to	sofosbuvir,	 is	 influenced	by	CYP3A	activity.	However,	a	
dose	adjustment	of	 individual	components	 is	complicated	since	all	
DAA	combination	treatments	are	available	as	fixed‐dose	combina‐
tions,	except	 for	sofosbuvir	and	daclatasvir,	which	are	available	as	
separate	 formulations.	Data	 from	phase	 IV	 trials	 suggest	 that	 sus‐
tained	virological	response	is	not	related	to	plasma	concentrations	
of	 glecaprevir	 in	nonpregnant	patients	on	high‐dose	proton	pump	
inhibitors	(PPIs),	implying	that	the	levels	were	well	above	the	thera‐
peutic	threshold.	A	slight	decrease	in	glecaprevir	exposure,	caused	
by	moderate	CYP3A4	induction	due	to	pregnancy,	 is	therefore	ex‐
pected	to	be	of	less	clinical	relevance.67,68	Regarding	daclatasvir,	the	
recommended	daclatasvir	dose	of	60	mg	QD	is	increased	to	90	mg	
QD	 when	 co‐administered	 with	 moderate	 inducers	 of	 CYP3A4A,	
as	 reductions	 in	 exposure	 of	 25%	have	 been	observed	 frequently	
for	 CYP3A4	 substrates.62	 A	moderate	 increase	 in	 CYP3A	 activity	
due	to	pregnancy	may	also	require	an	increase	in	daclatasvir	dose.	
However,	the	clinical	relevance	of	increased	CYP3A4	metabolism	for	
daclatasvir	 in	pregnancy	is	unknown	as	its	oral	clearance	is	signifi‐
cantly	lower	in	women	than	in	men,	resulting	in	higher	exposure	in	
women.69
2.4 | Excretion
Elimination	of	DAAs	(except	for	sofosbuvir)	occurs	mainly	via	biliary	
excretion	 as	 parent	 drug.	 Pregnancy	 may	 alter	 the	 expression	 of	
drug	transporters	in	metabolising	and	eliminating	organs,	but	there	
is	 little	quantitative	 information	on	 the	 influence	of	pregnancy	on	
transporter	activity	in	the	basolateral	and	canalicular	membrane	of	
hepatocytes,	and	the	resulting	effect	on	DAA	excretion.	Due	to	this	
lack	of	knowledge,	no	pregnancy	physiologically‐based	pharmacoki‐
netic	(PBPK)	models	have	been	published	which	simulate	the	role	of	
biliary	 drug	 excretion.70	 Sofosbuvir	 is	mainly	 renally	 eliminated	 as	
its	pharmacologically	 inactive	metabolite	GS‐331007	 (78%)	and	to	
a	lesser	extent	as	unchanged	sofosbuvir	(3.5%).	Because	pregnancy	
leads	to	an	increase	in	renal	blood	flow	and	glomerular	filtration	rate,	
renal	clearance	of	sofosbuvir	may	be	increased	during	pregnancy.	It	
is,	 however,	 unclear	whether	 this	 could	 influence	plasma	 levels	 to	
the	point	of	requiring	dose	adjustment.55,71
2.5 | Drug‐drug interactions (DDIs) in case of 
maternal viral co‐infection
For	the	treatment	of	maternal	hepatitis	B	co‐infection,	 tenofovir	
disoproxil	fumarate	(TDF)	is	preferred.72	As	TDF	may	also	be	part	
of	combination	antiretroviral	therapy	(cART)	for	treatment	of	HIV,	
literature	on	DDIs	between	cART	and	DAAs	can	be	consulted.65 
DDIs	between	HCV	and	cART	are	an	 important	consideration	 in	
the	treatment	of	(pregnant)	HCV/HIV	co‐infected	women,14,15 and 
are	 well	 described	 in	 the	 literature.65,73	 However	 pregnancy‐in‐
duced	alterations	could	also	influence	either	HCV	and/or	HIV	drug	
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exposure	as	a	third	factor,	making	the	translation	of	DDIs	from	the	
nonpregnant	patient	population	to	pregnant	women	complicated.	
Here	we	do	not	elaborate	on	drug	combinations	that	are	already	
contra‐indicated	in	the	nonpregnant	population,	but	focus	on	spe‐
cific	DDIs	 that	may	be	of	concern	due	to	 the	possible	effects	of	
pregnancy	 on	 drug	 exposure.	 A	 first	 example	 is	 efavirenz,	 com‐
monly	 used	 as	 part	 of	 cART,	 but	 known	 to	 decrease	 daclatasvir	
exposure	via	induction	of	CYP3A4,	with	an	area	under	the	plasma	
concentration‐time	curve	(AUC)	geometric	mean	ratio	(GMR)	with	
90%	CI	of	0.68	(0.60,	0.78).74	The	recommended	daclatasvir	dose	is	
therefore	increased	(90	mg	instead	of	60	mg	once	daily)	in	patients	
using	 efavirenz.	 In	 pregnant	 women,	 an	 increase	 of	 daclatasvir	
dose	may	 also	 be	warranted	 as	 pregnancy	 also	 affects	 CYP3A4	
activity,	 resulting	 in	 lower	daclatasvir	plasma	 levels	compared	to	
nonpregnant	patients.	In	addition,	use	of	efavirenz	with	ledipasvir	
results	in	a	reduction	of	ledipasvir	exposure	(AUC	GMR	[90%	CI]	
of	0.66	[0.59,	0.75]);	the	pregnancy‐related	increase	in	gastric	pH	
is	likely	to	also	decrease	ledipasvir	exposure.57	Lastly,	concomitant	
use	of	darunavir/ritonavir	with	sofosbuvir/velpatasvir/voxilaprevir	
results	 in	 higher	 voxilaprevir	 due	 to	 inhibition	 of	 organic‐anion‐
transporting	 polypeptide	 (OATP)‐1B1,	 P‐glycoprotein	 (P‐gp)	 and	
CYP3A,	 with	 an	 AUC	GMR	 (90%	 CI)	 of	 2.43	 (2.15,	 2.75),	 but	 is	
considered	to	be	not	clinically	relevant	in	the	nonpregnant	popu‐
lation.75	During	pregnancy	twice	daily	darunavir,	 instead	of	once	
daily,	 is	 recommended	 and	 therefore	 concomitant	 use	 of	 daru‐
navir/ritonavir	 and	 sofosbuvir/velpatasvir/voxilaprevir	 should	 be	
contra‐indicated.
According	 to	 the	 guidelines,	 dolutegravir	 has	 low	 potential	
for	 DDIs	 and	 may	 therefore	 seem	 of	 particular	 interest	 for	 use	
in	women	 living	with	HCV	 and	HIV.65	However,	 a	 recent	 report	
highlighted	an	increased	incidence	of	neural	tube	defects	associ‐
ated	with	dolutegravir	use	around	the	time	of	conception.	Further	
safety	data	are	awaited	to	confirm	or	refute	this	finding	and	in	the	
meantime	dolutegravir	use	around	the	time	of	conception	should	
be	avoided,76	although	if	used	after	the	first	trimester,	there	is	no	
increased	 risk	 of	 neural	 tube	 defects.	As	 the	 choice	 for	HCV	 as	
well	as	cART	is	mainly	dependent	on	local	drug	availability,	which	
is	limited	in	low‐income	countries,	it	might	not	be	possible	to	pre‐
scribe	 the	 combination	 of	 preference.	 Based	 on	 available	 data	
regarding	possible	DDIs	between	DAAs	and	cART,	and	taking	po‐
tential	effects	of	pregnancy	on	 their	pharmacokinetics	 into	con‐
sideration,	 the	choice	of	combination	 treatment	should	be	made	
by	local	physicians.
3  | PL ACENTAL HANDLING OF DIREC T-
AC TING ANTIVIR AL S
Drug	transport	across	 the	placental	barrier	 is	a	major	determinant	
of	foetal	exposure	and	toxicity.	However,	for	some	conditions	foetal	
exposure	to	maternally	administered	drugs	could	potentially	provide	
pre‐exposure	prophylaxis	and	thereby	reduce	the	chance	of	vertical	
transmission,	as	has	been	hypothesised	for	HIV.77
3.1 | Placental handling in human pregnancy
For	 ethical	 reasons,	 pregnant	women	have	historically	 often	been	
excluded	from	clinical	trials	in	the	drug	development	process,	result‐
ing	in	a	gap	of	knowledge	regarding	both	maternal	and	foetal	drug	
exposure	throughout	gestation.	However,	recent	reports	on	the	im‐
portance	of	conducting	pharmacological	research	in	pregnancy	and	
possible	 research	 strategies	 highlight	 that	 times	 are	 changing.78,79 
To	our	knowledge,	information	on	DAA	exposure	during	pregnancy	
is	 currently	 limited	 to	 three	 conference	 abstracts.	However,	 none	
of	these	studies	collected	data	on	foetal	exposure	 (eg	as	umbilical	
cord	blood	concentrations)	as	treatment	was	either	discontinued	or	
completed	during	pregnancy	and	it	is	therefore	not	known	whether	
or	how	well	these	DAAs	cross	the	human	placental	barrier	in	vivo.
3.2 | Placental handling in pre‐clinical research
Studies	on	placental	 handling	of	DAAs	 are	 solely	 based	on	devel‐
opmental	toxicology	studies	in	animal	models.	As	shown	in	Table	2,	
placental	 transfer	of	sofosbuvir,	daclatasvir,	glecaprevir,	pibrentas‐
vir,	 grazoprevir	 and	 elbasvir	 has	 been	 observed	 in	 rats.	 Placental	
transfer	of	grazoprevir	and	elbasvir	has,	in	addition	to	rats,	also	been	
observed	 in	rabbits,	but	to	a	minimal	extent.	However,	because	of	
interspecies	 differences	 in	 placental	 anatomy,	 placental	 transfer	
data	 from	animal	 studies	 is	 of	 poor	 translational	 value.	Compared	
to	the	placenta	of	rabbit,	rat	and	mouse,	the	structure	of	the	human	
placenta	differs	in	gross	shape,	histology	of	the	maternofoetal	inter‐
face	and	type	of	maternofoetal	interdigitation,	which	may	all	affect	
placental	drug	transfer.80
3.3 | Prediction of placental drug handling ex vivo
To	predict	transfer	of	drugs	across	the	human	placenta	in	vivo,	data	
from	 animal	 studies	 may	 be	 combined	 with	 information	 on	 drug‐
specific	 physicochemical	 characteristics.	 Comparing	 DAAs	 based	
on	 their	 specific	 physicochemical	 properties	 provides	 information	
on	 potential	 changes	 in	 their	 pharmacokinetics	 during	 pregnancy	
(Chapter	2)	and	a	similar	approach	can	yield	estimates	of	placental	
transfer,	and	hence	provides	a	rough	estimate	of	foetal	exposure.	A	
review	by	Giaginis	et	al	summarised	the	factors	affecting	transport	
of	 drugs	 across	 the	 placental	 barrier.81	 In	 general,	 maternofoetal	
exchange	 increases	 with	 gestational	 age	 because	 of	 physiological	
changes,	 eg	 reduced	 membrane	 thickness	 and	 increased	 uterine	
blood	flow,	inherent	to	the	increased	foetal	demand	of	oxygen	and	
nutrients.80	Passive	diffusion	is	the	major	route	of	placental	transport	
and	 is	 responsible	 for	 rapid	 transfer	of	 lipophilic	drugs	with	a	mo‐
lecular	weight	of	<500	Da.	Larger	molecules	may	also	be	subjected	
to	passive	diffusion,	which	is	a	relatively	slow	process	81;	all	DAAs	
are	highly	 lipophilic,	 indicated	by	a	 log	P	>2.5	 (except	for	sofosbu‐
vir,	log	P	=	1.62),	favouring	effective	passive	diffusion.	On	the	other	
hand,	 their	 high	molecular	weight	 (all	 >500	Da)	may	hamper	or	 at	
least	slow	the	process.	In	addition,	the	degree	of	ionisation	and	pro‐
tein	binding	also	influence	the	rate	and	extent	of	placental	transfer.	
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Protein	binding	will	contribute	 to	 trapping	of	drug	 in	 the	 foetal	or	
maternal	circulation,	and	as	maternal	and	foetal	plasma	protein	con‐
centrations	 differ	 and	 change	with	 advancing	 gestational	 age,	 the	
maternal‐to‐foetal	ratio	of	total	drug	plasma	concentration	may	vary	
accordingly.82	Next	 to	passive	diffusion,	drug	 transport	across	 the	
placental	barrier	may	also	be	carrier‐mediated,	either	as	facilitated	
diffusion	 or	 via	 active	 transporters.	 All	 DAAs	 included	 in	 this	 re‐
view	are	ATP‐binding	cassette	(ABC)	transporter	substrates	of	P‐gp	
(ABCB1)	 and/or	Breast	Cancer	Resistance	Protein	 (BCRP/ABCG2).	
As	these	efflux	transporters	are	expressed	at	the	apical	side	of	the	
syncytiotrophoblast	layer,	they	possibly	play	a	role	in	reducing	foetal	
exposure.	Xenobiotics	interacting	with	these	transporters	may	also	
influence	placental	transfer	of	DAAs.83	Since	placental	transporter	
expression	changes	during	pregnancy,	placental	transfer	may	be	also	
dependent	on	timing	of	treatment	during	pregnancy.	A	reduction	in	
P‐gp	mRNA	and	protein	levels	from	first	trimester	towards	term	has	
been	reported,	 likely	related	to	the	general	decrease	in	foetal	pro‐
tection	after	the	critical	period	of	organogenesis.	Therefore,	 there	
is	 a	 greater	potential	 of	P‐gp	 substrates	 (eg	most	DAAs),	 to	 reach	
the	unborn	child	with	advancing	gestational	age.	Literature	on	BCRP	
expression	throughout	gestation	is	inconsistent.84
As	outlined	above,	different	 factors	either	 facilitate	or	 impede	
drug	transport	across	 the	placental	barrier.	Hence,	 it	 is	difficult	 to	
estimate	the	extent	of	placental	transport	of	a	specific	drug	at	a	spe‐
cific	time	point	during	pregnancy.	In	addition	to	in	vitro	techniques	
using	 immortalised	 cell	 lines	 or	 tissue	 explants,	 computer‐assisted	
modelling	 attempts	 are	 useful	 to	 explore	 the	 contribution	 of	 the	
physicochemical	 properties	 to	 placental	 transport.85,86	 The	 dual	
side	placental	perfusion	model	has	proven	to	be	a	valid	experimen‐
tal	method	to	study	the	transport	of	xenobiotics	ex	vivo	and	is	cur‐
rently	used	extensively	to	investigate	placental	passage.87	As	stated	
before,	it	is	hypothesised	that	the	extent	of	placental	drug	transfer	
TA B L E  2  Safety	data	from	reproductive	teratogenicity	studies	of	DAAs	in	pregnancy
DAA therapy Prenatal and postnatal development Placental transfer Lactation
DAA 
combination Drug
Safety 
concerns?
Tested animal species  
(Dose and duration)
Transfer 
across 
placenta
Tested animal species 
(% of maternal plasma 
levels)
Transfer into milka 
(% of maternal 
plasma levels)
SOF/DAC SOFb No Rats:	10x	RHD,	GD6‐18,	GD6‐LD20
Rabbits:	28x	RHD,	GD6‐19
Yes Rats Yes	(80%)
DAC Yesc Rats:	4x	RHD,	GD7‐19
Rabbits:	16x	RHD,	GD6‐15
Yes Rats Yes	(170%‐200%)
SOF/LDV SOFb No Rats:	10x	RHD,	GD6‐18,	GD6‐LD20
Rabbits:	28x	RHD,	GD6‐19
Yes Rats Yes	(80%)
LDV Possiblec Rats:	4x	RHD,	GD6‐18
Rabbits:	2x	RHD,	GD7‐20
Unknown Not	tested Yes
SOF/VEL	
SOF/VEL/VOX
SOFb No Rats:	10x	RHD,	GD6‐18,	GD6‐LD20
Rabbits:	28x	RHD,	GD6‐19
Yes Rats Yes	(80%)
VEL Possibled Rats:	6x	RHD,	GD6‐17,	GD6‐LD20
Rabbits:	0.5‐0.7x	RHD,	GD7‐20
Mice:	31x	RHD,	GD6‐15
Not	evident Rats Yes	(173%)
VOX No Rats:	141x	RDH,	GD6‐LD20
Rabbits:	4x	RHD,	GD7‐19
Unknown Not	tested Yes
GZR/ELB GZR No Rats:	117x	RHD,	GD6‐20,	GD6‐LD20
Rabbits:	41x	RHD,	GD7‐20
Yes Rats	(89%)
Rabbits	(7%)
Yes	(400%)
ELB No Rats:	10x	RHD,	GD6‐20,	GD6‐LD20
Rabbits:	18x	RHD,	GD7‐20
Yes Rabbits	(0.8%)
Rats	(2.2%)
Yes	(87%)
GLE/PIB GLE Possiblee Rats:	53x	RHD,	GD6‐18,	GD6‐LD20
Rabbits:	0.07x	RHD,	GD7‐19
Yes Rats Yes	(<8%)
PIB No Rabbits:	1.5x	RHD	GD7‐19
Mice:	51x	RHD	GD6‐15,	GD6‐LD20
Yes Mice Yes	(150%)
Abbreviations:	DAC,	daclatasvir;	ELB,	elbasvir;	GD,	gestation	day;	GLE,	glecaprevir;	GZR,	grazoprevir;	LD,	lactation	day;	LDV,	ledipasvir;	PIB,	pibren‐
tasvir;	RHD,	recommended	human	dose;	SOF,	sofosbuvir;	VEL,	velpatasvir;	VOX,	voxilaprevir.
aTransfer	into	milk	was	studied	in	rats.	
bExposure	to	predominant	circulating	metabolite	of	sofosbuvir	(GS‐331007).	
cAt	a	high	dose	(4.6‐fold	RHD),	an	increased	incidence	of	skeletal	variations	(vertebrae,	sternea,	ribs)	in	rats	was	observed.	These	effects	are	likely	
related	to	a	decrease	in	maternal	body	weight	gain	and	decreased	food	intake.	
dA	possible	teratogenic	effect	was	indicated	in	rabbits	where	an	increase	in	total	visceral	malformations	was	seen	in	exposed	animals	at	AUC	expo‐
sures	up	to	0.7‐fold	RHD	for	SOF/VEL	and	0.5‐fold	RHD	for	SOF/VEL/VOX.	
eMaternal	toxicity	with	some	embryofoetal	toxicity	precluded	the	ability	to	evaluate	glecaprevir	in	the	rabbit	at	human	clinical	exposures.	
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increases	 towards	 term.80	 Therefore,	 data	 from	 ex	 vivo	 placental	
perfusion	 experiments	 using	 term	 placentas	 potentially	 overesti‐
mate	foetal	exposure	during	earlier	phases	of	pregnancy.87	For	a	va‐
riety	of	drugs	studied,	transfer	across	term	placentas	ex	vivo	shows	
good	correlations	with	in	vivo	maternal	and	cord	blood	concentra‐
tion.	Hence,	data	from	ex	vivo	placental	perfusion	experiments	may	
also	be	used	to	rank	the	various	DAAs	with	regard	to	their	potential	
to	cross	the	placenta.88
4  | SAFET Y OF DIREC T-AC TING 
ANTIVIR AL S DURING PREGNANCY
In	 the	absence	of	 conclusive	evidence	 from	DAA	exposure	during	
human	 pregnancy,	 assessments	 of	 DAA	 safety	 are	 based	 on	 data	
derived	from	animal	reproduction	toxicology	studies.	Table	2	sum‐
marises	 the	 results	 of	 these	 pre‐clinical	 studies	 on	 embryofoetal	
toxicity,	 teratogenicity,	 placenta	 transfer	 and	 breast	 milk.	 The	 lit‐
erature	search	strategy	can	be	found	in	Appendix	S1.	Although	the	
majority	of	the	adverse	effects	of	drugs	are	related	to	direct	foetal	
exposure	because	of	 placental	 transfer,	 drugs	may	 also	 affect	 the	
developing	 foetus	 indirectly	 by	 disturbing	 placental	 function.89 
However,	 the	 species‐specific	 placental	 physiology,	 as	well	 as	 im‐
munological	 and	 endocrinological	 differences	 hamper	 the	 transla‐
tion	of	placental	drug	effects	from	animal	studies.90	A	large	registry	
of	 infants	 intrauterine‐exposed	to	DAAs	 is	needed	to	assess	 long‐
term	effects	in	humans.	Such	an	approach	has	been	undertaken	for	
HIV,	 the	 Antiretroviral	 Pregnancy	 Registry,	 and	 has	 been	 proven	
to	be	 successful	 in	monitoring	 effects	 of	 intrauterine	 exposure	 to	
	antiretrovirals.91	Adding	HCV	to	an	existing	pregnancy	registry	may	
be	an	option	worth	considering.
4.1 | Sofosbuvir/daclatasvir
The	 only	 data	 available	 on	 sofosbuvir/daclatasvir	 in	 human	 preg‐
nancy	 include	 one	 study	 on	 accidental	 sofosbuvir/daclatasvir	 ex‐
posure	 around	 the	 time	 of	 conception	 (n	 =	 7).	 No	 adverse	 birth	
outcomes	 were	 reported	 but	 one	 infant	 tested	 HCV	 positive	 at	
18	months	with	low	viral	load,	which	is	not	unexpected	as	all	women	
discontinued	therapy	early,	before	week	9	of	gestation.53
Sofosbuvir	 administration	 showed	 no	 adverse	 effects	 in	 pre‐
clinical	 reproduction	 toxicology	 studies	 using	 rabbits	 at	 exposure	
levels	comparable	to	10‐fold	the	recommended	human	dose	(RHD).	
As	sofosbuvir	could	not	be	detected	in	rodent	plasma	probably	due	
to	high	esterase	activity,	assessment	of	reproductive	toxicity	tests	
in	 rats	 are	 based	 on	 exposure	 to	 the	 major	 (inactive)	 metabolite	
GS‐331007.	At	GS‐331007	exposure	levels	following	a	10‐fold	RHD,	
no	effect	on	 intrauterine	development	or	any	malformations	were	
seen	 in	 rats.92,93	 As	 sofosbuvir	 was	 detectable	 in	 human	 plasma,	
data	 from	 rodent	 studies	 regarding	 sofosbuvir	 exposure	 should	
be	 interpreted	with	caution.	For	daclatasvir,	 embryofoetal	 toxicity	
(external	and/or	visceral	malformations)	in	rabbits	and	rats	was	re‐
ported	by	the	EMA.	However,	exposure	in	rats	and	rabbits	was	4.6	
and	 16‐fold	 RHD	 respectively.94	 Remarkably,	 the	 Food	 and	 Drug	
Administration	(FDA)	reported	no	concerns	for	embryofoetal	toxic‐
ity	in	rats	when	exposed	to	6x	RHD	and	in	rabbits	when	exposed	to	
22‐fold	RHD.95
In	 the	general	 patient	population,	 this	DAA	combination	has	 a	
favourable	safety	profile.	The	most	frequently	reported	adverse	re‐
actions	were	 fatigue,	headache	and	nausea.71,74	A	 special	warning	
for	the	use	of	sofosbuvir	(in	combination	with	either	daclatasvir	or	
ledipasvir)	 and	amiodarone	was	based	on	observed	bradycardia	 in	
several	patients.96
4.2 | Sofosbuvir/ledipasvir
Data	on	 sofosbuvir/ledipasvir	 use	during	pregnancy	 are	 limited	 to	
two	 conference	 abstracts:	 one	 study	 performed	 in	 India	 included	
pregnant	 women	 living	 with	 HCV	 who	 requested	 treatment	 be‐
cause	 of	 anxiety	 about	 vertical	 transmission	 (n	 =	 15),	 and	 DAAs	
were	started	during	the	second	and	early	third	trimester54;	and	the	
other,	previously	mentioned,	is	a	phase	I	trial	of	sofosbuvir/ledipasvir	
started	during	the	second	trimester	of	pregnancy	 (n	=	8)	 from	the	
USA.52	Both	studies	reported	no	safety	concerns;	there	were	are	no	
cases	of	vertical	transmission	to	date	in	the	USA	study,	but	the	num‐
ber	is	yet	to	be	reported	for	the	Indian	study.	Considering	the	small	
number	of	women	in	the	two	studies,	a	lack	of	vertical	transmission	
would	not	be	unusual	even	in	the	absence	of	treatment.
The	decision	to	study	sofosbuvir/ledipasvir	in	a	clinical	setting	is	
supported	by	a	favourable	embryofoetal	safety	profile	based	on	pre‐
clinical	studies.	As	stated	earlier	in	this	review,	sofosbuvir	use	seems	
safe	 for	 the	 developing	 offspring	 in	 rats	 and	 rabbits.	 At	 exposure	
levels	of	3.4‐fold	RHD,	minor	effects	of	ledipasvir	on	fertility	of	fe‐
male	rats	were	reported.	However,	this	was	not	seen	at	2‐fold	RHD	
and	effects	were	 likely	 related	 to	non‐adverse	maternal	 toxicity.97 
The	FDA	reported	that	there	are	no	clear	adverse	effects	on	foetal	
development	in	rats	and	rabbits	at	4‐fold	and	2.3‐fold	RHD	respec‐
tively.	However,	a	 lower	body	weight	of	the	offspring	 in	rats	at	an	
exposure	level	of	4‐fold	RHD	is	reported	by	the	EMA	and	at	slightly	
higher	 exposure	 levels	 (4.6‐fold	 RHD),	 an	 increased	 incidence	 of	
skeletal	variations	was	observed.57,98	In	the	absence	of	other	toxicity	
findings,	this	effect	on	the	offspring	may	be	related	to	non‐adverse	
maternal toxicity.
In	terms	of	adverse	events,	fatigue	and	headache	were	reported	
in	adult	patients	treated	with	ledipasvir/sofosbuvir.57
4.3 | Sofosbuvir/velpatasvir (±voxilaprevir)
The	EMA	reports	a	possible	 teratogenic	effect	 (visceral	malforma‐
tions)	due	to	velpatasvir	exposure	of	0.7‐fold	RHD	in	pregnant	rab‐
bits;	however,	according	to	the	FDA	label,	this	is	written	as	being	of	
“no	significant	effect”.	Mice	and	rat	studies	found	no	embryofoetal	
adverse	effects	at	23‐fold	RHD	and	4‐fold	RHD	respectively.	There	
was	no	evidence	of	placental	transfer	of	velpatasvir	as	it	could	not	
be	detected	 in	 litter	 after	 a	 single	dose	of	30	mg/kg	on	gestation	
day	13	or	18.	Maternal	voxilaprevir	administration	did	not	result	in	
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adverse	embryofoetal	effects	in	rats	(141‐fold	RHD)	and	rabbits	(4‐
fold	RHD).	No	data	on	placental	transfer	of	voxilaprevir	 in	animals	
have	been	reported.99‐102
The	most	common	adverse	effects	seen	in	clinical	studies	were	
headache,	 fatigue	 and	 nausea.	 When	 combined	 with	 voxilapre‐
vir,	 diarrhoea	 and	 nausea	were	 also	 reported	 as	 common	 adverse	
events.58,75
4.4 | Grazoprevir/elbasvir
Grazoprevir	 and	 elbasvir	 reproduction	 studies	 have	 failed	 to	 re‐
veal	any	adverse	effects	 in	rats	 (10‐fold	RHD)	and	rabbits	 (18‐fold	
RHD).103,104
In	patients	with	HCV,	reported	adverse	reactions	were	fatigue	and	
headache	with	a	special	warning	for	plasma	liver	enzyme	(ALT)	eleva‐
tions.	The	 rate	of	 late	ALT	elevations	during	 treatment	was	directly	
related	to	plasma	exposure	to	grazoprevir	and	generally	occurred	from	
approximately	8	weeks	after	start	of	treatment.	These	late	ALT	eleva‐
tions	were	typically	asymptomatic	and	resolved	with	ongoing	therapy	
with	grazoprevir/elbasvir	or	after	completion	of	therapy.105
4.5 | Glecaprevir/pibrentasvir
Registration	files	state	that	either	glecaprevir	administration	in	rats	
(63‐fold	RHD)	or	pibrentasvir	administration	in	mice	(100‐fold	RHD)	
did	not	result	in	reproductive	toxic	effects.	However,	this	conclusion	
was	considered	questionable	because	maternal	 toxicity	with	some	
embryofoetal	 toxicity	precluded	the	ability	 to	evaluate	glecaprevir	
in	rabbits	at	human	clinical	exposures.106,107
In	 clinical	 studies,	 the	most	 commonly	 reported	 adverse	 reac‐
tions	were	 fatigue	 and	headache.	Occasionally,	 elevations	of	 total	
bilirubin	levels	have	been	reported	in	patients	using	glecaprevir/pi‐
brentasvir.	The	effect	 is	more	pronounced	with	higher	glecaprevir	
plasma	levels	and	is	likely	due	to	glecaprevir‐mediated	inhibition	of	
bilirubin	 transport	 and	metabolism.108	 Although	maternal	 bilirubin	
elevations	are	asymptomatic	and	transient,	the	effects	on	the	foetus	
may	be	questionable	as	unconjugated	bilirubin	can	cross	the	placen‐
tal barrier.109	Therefore,	it	may	be	hypothesised	that	high	maternal	
bilirubin	levels	may	increase	the	risk	of	neonatal	jaundice.
5  | SAFET Y OF DIREC T-AC TING 
ANTIVIR AL S DURING THE L AC TATION
As	 studies	 have	 shown	 that	 avoidance	 of	 breastfeeding	 does	 not	
seem	 to	 reduce	 the	 chance	 of	 vertical	 HCV	 transmission,	 breast‐
feeding	is	considered	safe	among	women	with	chronic	HCV,	except	
for	women	with	cracked	nipples.110	Since	breastfeeding	is	currently	
not	contra‐indicated	in	these	patients	living	with	HCV,	it	is	important	
to	gather	information	of	the	potential	use	and	safety	of	DAAs	during	
the	lactation	period.
To	 evaluate	 safety	 of	 drug	 use	 during	 the	 lactation	 period	 the	
following	aspects	should	be	considered:	the	effect	of	drugs	on	milk	
production;	drug	concentrations	in	milk;	and	the	effects	of	exposure	
on	the	breastfed	child.	In	the	absence	of	human	data,	data	on	DAA	
exposure	in	milk	are	limited	to	rat	studies.	They	should	be	interpreted	
with	caution	due	to	species‐specific	differences	in	lactation	physiol‐
ogy	such	as	mammary	gland	anatomy,	storage	and	release	of	milk	into	
ducts,	protein	and	fat	composition	of	milk	and	the	expression	of	drug	
transporters	in	mammary	tissue,	as	these	factors	play	a	major	role	in	
the	extent	passage	of	drugs	into	milk.111	Data	obtained	from	rat	studies	
showed	that	DAAs	are	transferred	into	milk,	but	no	effects	on	growth	
and	development	were	observed	in	nursing	pups	exposed	to	DAAs	via	
milk.97,99,104,107	Maternal	plasma‐to‐milk	ratios	have	been	reported	to	
differ	considerably	between	DAAs	in	rat	studies.	Whereas	glecaprevir	
concentrations	in	milk	are	<8%	of	maternal	plasma	levels,	grazoprevir	
milk	concentrations	exceed	maternal	plasma	concentrations	(400%).	
This	disparity	in	extent	of	milk	transfer	is,	however,	difficult	to	explain	
based	on	the	physicochemical	differences	and	transporter	profiles	of	
the	two	compounds.112	Grazoprevir	and	glecaprevir	have	a	compara‐
ble	molecular	weight	with	a	similar	degree	of	plasma	protein	binding.	
Moreover,	glecaprevir	is	known	to	be	a	BCRP	substrate,	whereas	gra‐
zoprevir	is	not.	As	this	transporter	is	considered	to	contribute	to	ex‐
cretion	of	drugs	into	milk,113	the	proportion	of	glecaprevir	transferred	
to	milk	is	expected	to	be	high,	but	extensive	plasma	protein	binding	
impedes	its	transfer	into	breastmilk.
6  | DISCUSSION
There	are	multiple	 reasons	 to	either	 consider	or	defer	DAA	 treat‐
ment	 during	 pregnancy	 as	 reviewed	 extensively	 by	 others.7,114,115 
Although	the	AASLD/IDSA	guidelines	recommend	universal	screen‐
ing	of	pregnant	women,24	no	DAA	regimen	is	currently	approved	for	
treatment	 during	 pregnancy	 because	 of	 insufficient	 human	 safety	
and	efficacy	data	and	treatment	is	therefore	delayed	until	after	de‐
livery.	The	high	chance	of	loss	to	follow‐up	of	both	mother	and	her	
HCV‐exposed	child	 in	many	settings,	 together	with	 loss	of	health‐
care	insurance	after	pregnancy	may	complicate	adequate	maternal	
and	 paediatric	 treatment,	 highlighting	 the	 pregnancy	 period	 as	 a	
unique	window	of	opportunity	to	both	cure	the	mother	and	prevent	
vertical	transmission	of	HCV.46,116
Standard	dosing	 regimens	of	 currently	used	DAAs	may	be	 sub‐
optimal	 for	 the	 pregnant	 patient	 population	 as	 pregnancy‐induced	
pharmacokinetic	 changes	 may	 influence	 maternal	 drug	 exposure,	
hence	efficacy	of	 the	drugs.	The	expected	 increased	elimination	of	
DAAs,	 both	 because	 of	 a	 potentially	 increased	 biliary	 excretion	 as	
well	 as	 induction	 of	metabolising	 enzymes,	may	 potentially	 lead	 to	
subtherapeutic	levels.	This	pregnancy‐induced	effect	is	expected	to	
be	less	pronounced	for	sofosbuvir/ledipasvir	and	glecaprevir/pibren‐
tasvir	compared	to	other	DAA	combinations.	Instead	of	adjusting	the	
dose—which	 is	 rarely	 done	 in	 clinical	 practice—a	DAA	 combination	
less	prone	to	pregnancy‐induced	effects	could	be	chosen,	if	available.
Apart	 from	data	on	maternal	 exposure	 to	DAAs,	 early	data	on	
placental	handling	and	subsequent	foetal	exposure	are	important	to	
study	possible	placental	toxicity	of	DAAs	as	well	as	the	potential	of	
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DAAs	 to	 provide	 foetal	 pre‐exposure	 prophylaxis.	 Several	 ex	 vivo	
and	 in	vitro	models	may	provide	 insight	 into	pharmacokinetics,	 in‐
cluding	placental	transfer	of	drugs.87,117	The	ex	vivo	placental	perfu‐
sion	model,	using	human	term	placentas	yet	unexposed	to	drugs,	can	
be	helpful	in	studying	the	initial	phase	of	placental	DAA	handling	and	
may	provide	an	estimation	of	 foetal	exposure.	Subsequently,	preg‐
nancy‐PBPK	modelling	can	be	used	as	a	tool	to	assess	foetal	plasma	
levels	upon	maternal	administration	of	different	dosing	regimens.118 
In	the	view	of	potential	pre‐exposure	prophylaxis,	foetal	exposure	to	
DAAs	may,	next	to	maternal	viral	 load	reduction,	contribute	to	the	
reduced	risk	of	vertical	transmission.	In	contrast	to	HIV,	research	has	
yet	not	focused	on	the	use	of	DAAs	for	pre‐exposure	prophylaxis	in	
the	general	population.	Future	research	is	needed	to	clarify	the	role	
of	foetal	exposure	in	reducing	the	chance	of	vertical	transmission.
Most	DAAs	are	reported	to	cross	the	placental	barrier	in	either	
rats	 and/or	 rabbits	when	 administered	 early	 during	 pregnancy.	 In	
clinical	practice,	 it	 is	more	likely	that	treatment	will	be	started	late	
in	 pregnancy	 to	 avoid	 the	 critical	 period	 of	 foetal	 organogenesis.	
Therefore,	data	from	animal	reproductive	toxicity	studies	are	difficult	
to	extrapolate	to	the	human	clinical	situation	as	there	is	a	difference	
in	timing	of	treatment	and	because	of	the	large	interspecies	variabil‐
ity	in	placental	anatomy,	both	affecting	the	extent	of	placental	pas‐
sage.	Based	on	animal	studies,	it	is	likely	that	postpartum	exposure	
to	DAAs	may	occur	via	breastfeeding.	Nowadays,	breastfeeding	 is	
not	contra‐indicated	in	women	with	chronic	HCV.	However,	this	ad‐
vice	may	change	if	breastfeeding	women	are	treated	with	DAAs	in	
the	future,	given	that	fact	that	all	DAAs	are	detected	in	milk	of	rats,	
with	grazoprevir	levels	in	milk	being	400%	of	maternal	levels.
In	order	to	decide	on	the	timing	of	treatment,	it	is	not	only	im‐
portant	 to	assess	 the	most	critical	window	of	possible	 teratogenic	
effects	of	drug	exposure	(generally	the	earlier	phase	of	pregnancy),	
but	also	to	consider	the	timing	of	vertical	transmission	of	HCV.	As	
peripartum	blood‐blood	contact	may	be	the	most	important	source	
of	vertical	transmission,	maternal	HCV	RNA	should	be	undetectable	
during	delivery.	 Ideally,	 treatment	would	be	completed	before	de‐
livery.	In	that	case,	taking	into	account	that	women	living	with	HCV	
may	deliver	preterm,40	the	optimal	time	period	to	start	DAA	treat‐
ment	may	be	 at	 the	end	of	 the	 second	 trimester	 (at	 around	week	
23/24	of	gestation)	or	early	third	trimester	(at	around	27/28	weeks	
of	gestation),	 in	case	of	a	12‐	or	8	week	 treatment	period	 respec‐
tively,	and	may	have	to	be	extended	until	after	delivery	to	complete	
treatment.	For	 late	presenters	 (>28	weeks	of	gestation),	 treatment	
may	still	be	effective	as	DAAs	cause	a	rapid	viral	decline,	resulting	in	
undetectable	HCV	RNA	in	just	2‐4	weeks.119
The	choice	 for	a	 specific	DAA	combination	should	be	based	on	
safety	data	from	animal	reproductive	studies	and	safety	and	efficacy	
data	from	the	nonpregnant	patient	population.	Further	research	on	
safety,	PK	and	efficacy	in	pregnant	women	is	warranted	prior	to	im‐
plementation	 of	 treatment	 in	 this	 population.	 Research	 on	 the	 po‐
tential	 effect	 of	maternal	 DAA	 use	 on	 the	 state	 of	 foetal‐directed	
immune	 tolerance	 is	 of	 particular	 importance	 in	 this	 population	 as	
DAAs	are	thought	to	improve	the	proliferative	potential	of	HCV‐spe‐
cific	T	cell	response	again	which	may	decrease	immune	tolerance.120 
Furthermore,	 foetal	 exposure	 should	be	assessed,	 eg	by	measuring	
umbilical	 cord	 blood	 concentrations,	 when	 women	 continue	 treat‐
ment	 until	 after	 delivery.	 This	 information	 is	 needed	 to	 assess	 the	
potential	 of	 DAAs	 for	 pre‐exposure	 prophylaxis.	 Furthermore,	 an	
international	registry	is	needed	to	provide	a	safety	net	to	detect	ad‐
verse	effects	after	intrauterine	or	postpartum	DAA	exposure.
Next	to	safety	and	efficacy	data,	various	other	factors	have	to	be	
taken	into	account	to	decide	which	HCV	treatment	regimen	should	
be	preferred.	Firstly,	genotype	specificity	of	DAAs	plays	an	import‐
ant	role	as	the	phase	I	study	on	sofosbuvir/ledipasvir	in	pregnancy	
had	to	exclude	a	third	of	the	pregnant	women	for	participation	be‐
cause	of	genotype	2	or	3	 infection.52	As	genotyping	 is	 costly,	not	
feasible	 in	 all	 settings	 and	delays	 treatment	 start,	 future	 research	
may	focus	particularly	on	the	use	of	the	pan‐genotypic	DAA	com‐
binations	 glecaprevir/pibrentasvir	 and	 sofosbuvir/velpatasvir	 (with	
or	 without	 voxilaprevir)	 during	 pregnancy.	 Furthermore,	 the	 use	
of	 co‐medication	may	determine	 the	DAA	regimen	of	 first	 choice.	
In	 the	 case	 of	 HCV/HIV	 co‐infection,	 EFV	 should	 not	 be	 used	 in	
combination	with	any	DAA	and	when	boosted	PIs	are	part	of	cART,	
only	sofosbuvir/ledipasvir	or	sofosbuvir/velpatasvir	should	be	used	
concomitantly.	 If	women	use	proton	pump	 inhibitors	 (PPIs)	 during	
pregnancy,	neither	sofosbuvir/ledipasvir	nor	sofosbuvir/velpatasvir	
should	be	prescribed.	In	case	of	concomitant	use	of	strong	CYP3A4	
inducers,	 eg	 rifampicin,	 sofosbuvir/ledipasvir	 should	 be	 advised.	
Lastly,	 local	drug	availability	 and	costs	may	determine	which	drug	
will	be	prescribed,	despite	the	fact	that	this	DAA	regimen	may	not	
be	the	regimen	of	first	choice	based	on	animal	safety	data,	genotype	
specificity	or	potential	for	DDIs.	An	important	example	that	needs	
to	be	taken	into	consideration	is	the	widespread	use	of	sofosbuvir/
daclatasvir	in	Egypt,	which	is	one	of	the	countries	with	the	highest	
HCV	 prevalence	 worldwide.121	 Women	 becoming	 pregnant	 using	
daclatasvir	are	advised	to	stop	their	treatment	because	of	the	lack	
of	knowledge	regarding	safety	and	efficacy,53	despite	not	knowing	
whether	 cessation	 of	 treatment	 during	 pregnancy,	 likely	 resulting	
in	HCV	disease	relapse,	may	be	less	advantageous	than	continuing	
treatment.	Given	the	paucity	of	data	and	the	potential	exposure	to	
daclatasvir	during	conception	or	early	pregnancy,	research	is	needed	
on	 daclatasvir	 efficacy	 in	 human	pregnancy	 and	 global	 pregnancy	
registry	databases	are	warranted	to	assess	its	safety.
Ideally,	 a	 pan‐genotypic,	 safe	 and	 effective	 DAA	 combination	
would	be	available	to	all	pregnant	women	living	with	HCV,	diagnosed	
by	a	(cost‐effective)	universal	screening	programme.	However,	cost‐
effectiveness	of	 specific	DAA	combinations,	 local	drug	availability	
and	preferences	of	pregnant	women	themselves	and	their	treating	
physicians	play	a	dominant	role	and	these	factors	have	to	be	taken	
into	consideration.
7  | CONCLUSION
Treatment	 of	 HCV	 with	 DAAs	 during	 pregnancy	 and	 breastfeed‐
ing	is	not	currently	recommended	because	of	lack	of	data	on	safety,	
leaving	pregnant	women	diagnosed	with	HCV	untreated	until	after	
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delivery	(which	in	itself	maybe	distressing	for	the	mother	and	deter	
her	from	breastfeeding).	In	our	opinion,	this	window	of	opportunity	
to	 simultaneously	 improve	 maternal	 health	 and	 prevent	 vertical	
transmission	should	not	be	missed.	There	is	an	urgent	need	to	study	
DAAs	in	pregnant	and	breastfeeding	women	to	target	these	patient	
populations	as	well	as	their	HCV‐exposed	children	and	to	contribute	
to	the	HCV	elimination	goal	of	2030.
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